These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 19715841

  • 21. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
    Miller J, Mendez R, Pirsch JD, Jensik SC.
    Transplantation; 2000 Mar 15; 69(5):875-80. PubMed ID: 10755543
    [Abstract] [Full Text] [Related]

  • 22. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
    Sampaio EL, Pinheiro-Machado PG, Garcia R, Felipe CR, Park SI, Casarini DE, Moreira S, Franco MF, Tedesco-Silva H, Medina-Pestana JO.
    Clin Transplant; 2008 Mar 15; 22(2):141-9. PubMed ID: 18339132
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U, 2411 Study Investigators.
    Transplantation; 2009 Jul 15; 88(1):115-22. PubMed ID: 19584690
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug 15; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 28. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus.
    Wang SS, Chou NK, Chi NH, Wu IH, Chen YS, Yu HY, Huang SC, Wang CH, Ko WJ, Tsao CI, Sun CD.
    Transplant Proc; 2008 Oct 15; 40(8):2607-8. PubMed ID: 18929814
    [Abstract] [Full Text] [Related]

  • 29. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 15; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 30. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J, Wiseman AC.
    Transplantation; 2009 Jun 15; 87(11):1712-9. PubMed ID: 19502965
    [Abstract] [Full Text] [Related]

  • 31. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A.
    Transplant Proc; 2006 Dec 15; 38(10):3456-8. PubMed ID: 17175302
    [Abstract] [Full Text] [Related]

  • 32. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
    Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S, Prograf Study Group.
    Transplantation; 2005 Aug 15; 80(3):303-9. PubMed ID: 16082323
    [Abstract] [Full Text] [Related]

  • 33. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
    van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T.
    Clin Pharmacol Ther; 2009 Sep 15; 86(3):319-27. PubMed ID: 19494809
    [Abstract] [Full Text] [Related]

  • 34. Mycophenolate mofetil tolerability and dose changes in tacrolimus-treated renal allograft recipients.
    Pascual J, Ocaña J, Marcén R, Fernández A, Galeano C, Alarcón MC, Burgos FJ, Villafruela JJ, Ortuño J.
    Transplant Proc; 2006 Oct 15; 38(8):2398-9. PubMed ID: 17097946
    [Abstract] [Full Text] [Related]

  • 35. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.
    Boratyńska M, Banasik M, Patrzałek D, Klinger M.
    Ann Transplant; 2006 Oct 15; 11(2):51-6. PubMed ID: 17494290
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.
    Am J Transplant; 2017 May 15; 17(5):1358-1369. PubMed ID: 27775865
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Enteric-coated mycophenolate sodium versus mycophenolate mofetil maintenance immunosuppression: outcomes analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network database.
    Irish W, Arcona S, Gifford RJ, Baillie GM, Cooper M.
    Transplantation; 2010 Jul 15; 90(1):23-30. PubMed ID: 20445488
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.